Foster-Cheek Kaye I's Form 4 filing
Agios Pharmaceuticals, Inc. (AGIO) · filed Mar 7, 2024
- Accession no.
- 0001439222-24-000058
- Filed
- Mar 7, 2024
- Trade date
- Mar 5-6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $150.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foster-Cheek Kaye ICIK 0001312622 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2024 | Common stock | SSaleDisposed | −300 | $32.21 | −$9,663 | 11,224 | Direct | |
| Mar 6, 2024 | Common stock | SSaleDisposed | −4,415 | $31.99F1 | −$141,235.85 | 6,809 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $31.99 to $32.04. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.